Vyome (NASDAQ:HIND) Announces Quarterly Earnings Results

Vyome (NASDAQ:HIND) announced its quarterly earnings results on Tuesday. The company reported ($0.15) earnings per share for the quarter, Zacks reports. Vyome had a negative return on equity of 279.99% and a negative net margin of 270.58%.

Vyome Price Performance

Shares of NASDAQ HIND traded up $0.01 during mid-day trading on Tuesday, hitting $1.98. The company had a trading volume of 241,894 shares, compared to its average volume of 600,012. The business’s 50-day simple moving average is $2.32 and its 200-day simple moving average is $3.40. Vyome has a 12 month low of $1.75 and a 12 month high of $33.16. The firm has a market cap of $13.90 million, a P/E ratio of -0.02 and a beta of 1.38.

Institutional Investors Weigh In On Vyome

An institutional investor recently bought a new position in Vyome stock. Millennium Management LLC bought a new stake in Vyome Holdings, Inc. (NASDAQ:HIND) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned 0.80% of Vyome as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 22.06% of the company’s stock.

Analyst Ratings Changes

HIND has been the subject of a number of recent analyst reports. Zacks Research upgraded shares of Vyome to a “hold” rating in a report on Wednesday, May 6th. Weiss Ratings upgraded shares of Vyome from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Finally, Litchfield Hills Research initiated coverage on shares of Vyome in a report on Monday, May 4th. They set a “buy” rating for the company. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Vyome has a consensus rating of “Hold” and an average price target of $15.00.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.